MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR SOLID TUMORS
Summary
Amgen Inc. filed patent application US20260109776A1 covering human agonistic CD40 multispecific antibody constructs engineered to target the CD40 pathway on tumor-associated APCs for the treatment of solid tumors without systemic CD40 activation. The application was published on April 23, 2026 with filing date December 16, 2025 and application number 19421479, naming six inventors including Xin Yu, Jackson Egen, Fernando Garces, Shunsuke Takenaka, AeRyon Kim, and Deepali Sawant. CPC classifications span C07K 16 antibody constructs and A61P 35/04 for antineoplastic agents.
“The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
Amgen Inc. has obtained publication of a patent application (US20260109776A1) for mesothelin-targeted CD40 agonistic multispecific antibody constructs for treating solid tumors. The application claims a novel engineered molecule that targets the CD40 pathway on tumor-associated antigen-presenting cells while avoiding systemic CD40 activation. Six inventors are named: Xin Yu, Jackson Egen, Fernando Garces, Shunsuke Takenaka, AeRyon Kim, and Deepali Sawant.
Pharmaceutical and biotechnology companies developing CD40 agonist immunotherapies or multispecific antibodies for solid tumor indications should review this application to assess potential freedom-to-operate implications. Competitors in the CD40 pathway modulation space may need to evaluate whether Amgen's specific structural claims could cover their own development programs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS
Application US20260109776A1 Kind: A1 Apr 23, 2026
Assignee
AMGEN INC.
Inventors
Xin YU, Jackson EGEN, Fernando GARCES, Shunsuke TAKENAKA, AeRyon KIM, Deepali SAWANT
Abstract
The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.
CPC Classifications
C07K 16/2878 A61P 35/04 C07K 16/30 A61K 2039/505 C07K 2317/31 C07K 2317/33 C07K 2317/35 C07K 2317/522 C07K 2317/524 C07K 2317/526 C07K 2317/53 C07K 2317/565 C07K 2317/622 C07K 2317/75 C07K 2317/92
Filing Date
2025-12-16
Application No.
19421479
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.